hIL-2 NOG Publications

hIL-2 NOG Model Page

Filter publications by application: All Antibody-Dependent-Cellular Cytotoxicity (ADCC) Gene/Cell therapy Humanized Immuno-Oncology Immunology Immunotherapy Melanoma NK Oncology Patient Derived Xenograft (PDX) T And/Or B Cell Function Transplantation Research And Graft Versus Host Disease (GVHD)
Filter publications by model type: All Humanization Random integration transgene

Author(s)

(Date)

Paper Title

Citation

Model Type

Applications

Full Text

Liang F, et al.
Mouse over for full list
Liang F, Nilsson LM, Byvald F, Rezapour A, Taflin H, Nilsson JA, Yrlid U
(2022) A Fraction of CD8+ T Cells from Colorectal Liver Metastases Preferentially Repopulate Autologous Patient-Derived Xenograft Tumors as Tissue-Resident Memory T Cells. Cancers (Basel) 14(12)
Hofving T, et al.
Mouse over for full list
Hofving T, Liang F, Karlsson J, Yrlid U, Nilsson JA, Nilsson O, Nilsson LM
(2021) The Microenvironment of Small Intestinal Neuroendocrine Tumours Contains Lymphocytes Capable of Recognition and Activation after Expansion. Cancers (Basel) 13(17)
Oncology, Immuno-Oncology
Tatiana V. Kudling, et al.
Mouse over for full list
Tatiana V. Kudling, James H.A. Clubb, Dafne C.A. Quixabeira, Joao M. Santos, Riikka Havunen, Alexander Kononov, Camilla Heiniö, Victor Cervera-Carrascon, Santeri Pakola, Saru Basnet, Susanna Grönberg-Vähä-Koskela, Victor Arias, Ivan Gladwyn-Ng, Katri Aro, Leif Bäck, Jari Räsänen, Ilkka Ilonen, Kristian Borenius, Mikko Räsänen, Otto Hemminki, Antti Rannikko, Anna Kanerva, Johanna Tapper, Akseli Hemminki
(2022) Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression OncoImmunology, 11:1, DOI: 10.1080/2162402X.2022.2096572
Oncology, Patient Derived Xenograft (PDX), Immuno-Oncology
Arnaud M, et al.
Mouse over for full list
Arnaud M, Chiffelle J, Genolet R, Navarro Rodrigo B, Perez MAS, Huber F, Magnin M, Nguyen-Ngoc T, Guillaume P, Baumgaertner P, Chong C, Stevenson BJ, Gfeller D, Irving M, Speiser DE, Schmidt J, Zoete V, Kandalaft LE, Bassani-Sternberg M, Bobisse S, Coukos G, Harari A
(2022) Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nat Biotechnol
Muralidharan SV, et al.
Mouse over for full list
Muralidharan SV, Nilsson LM, Lindberg MF, Nilsson JA
(2020) Small molecule inhibitors and a kinase-dead expressing mouse model demonstrate that the kinase activity of Chk1 is essential for mouse embryos and cancer cells. Life Sci Alliance 3(8)
Çınar Ö, et al.
Mouse over for full list
Çınar Ö, Brzezicha B, Grunert C, Kloetzel PM, Beier C, Peuker CA, Keller U, Pezzutto A, Busse A
(2021) High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies. J Immunother Cancer 9(7)
Ny L, et al.
Mouse over for full list
Ny L, Rizzo LY, Belgrano V, Karlsson J, Jespersen H, Carstam L, Bagge RO, Nilsson LM, Nilsson JA
(2020) Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. Ann Oncol 31(2):266-273
Helleday T
Mouse over for full list
Helleday T
(2020) Using personalized immune-humanized xenograft mouse models to predict immune checkpoint responses in malignant melanoma: potential and hurdles. Ann. Oncol. 31(2):167-168
Forsberg EM, et al.
Mouse over for full list
Forsberg EM, Lindberg MF, Jespersen H, Alsén S, Olofsson Bagge R, Donia M, Svane IM, Nilsson O, Ny L, Nilsson LM, Nilsson JA
(2019) HER2 CAR-T cells eradicate uveal melanoma and T cell therapy-resistant human melanoma in interleukin-2 (IL-2) transgenic NOD/SCID IL-2 receptor knockout mice. Cancer Res.
Einarsdottir BO, et al.
Mouse over for full list
Einarsdottir BO, Karlsson J, Söderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, Brynjolfsson SF, Bagge RO, Carstam L, Scobie M, Koolmeister T, Wallner O, Stierner U, Berglund UW, Ny L, Nilsson LM, Larsson E, Helleday T, Nilsson JA
(2018) A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. Cell Death Dis 9(8):810
Humanization, Random integration transgene
T And/Or B Cell Function, Oncology, Melanoma, Humanized
Paul Volden, et al.
Mouse over for full list
Paul Volden, Azusa Tanaka, Dimitri Gimnopoulos, Magdalena Paterka, Iduna Fichtner
(2018) Cytokine-transgenic NOG mice engrafted with human peripheral blood cells support natural killer cell expansion   American Association for Cancer Research 2018 Conference
Humanization, Random integration transgene
Immunology, NK, Antibody-Dependent-Cellular Cytotoxicity (ADCC), Transplantation Research And Graft Versus Host Disease (GVHD), Immunotherapy, Immuno-Oncology, Gene/Cell therapy
Jespersen H, et al.
Mouse over for full list
Jespersen H, Lindberg MF, Donia M, Söderberg EMV, Andersen R, Keller U, Ny L, Svane IM, Nilsson LM, Nilsson JA
(2017) Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nat Commun 8(1):707
Humanization
Immunology, Oncology, Humanized
Ito R, et al.
Mouse over for full list
Ito R, Katano I, Kawai K, Yagoto M, Takahashi T, Ka Y, Ogura T, Takahashi R, Ito M
(2016) A novel xenogeneic graft-versus-host disease model for investigating the pathological role of human CD4+ or CD8+ T cells using immunodeficient NOG mice. Am. J. Transplant.
Katano I, et al.
Mouse over for full list
Katano I, Takahashi T, Ito R, Kamisako T, Mizusawa T, Ka Y, Ogura T, Suemizu H, Kawakami Y, Ito M
(2015) Predominant development of mature and functional human NK cells in a novel human IL-2-producing transgenic NOG mouse. J. Immunol. 194(7):3513-25
Close

Welcome! Tell us a little about yourself